Cargando…
Clinical management of molecular alterations identified by high throughput sequencing in patients with advanced solid tumors in treatment failure: Real-world data from a French hospital
BACKGROUND: In the context of personalized medicine, screening patients to identify targetable molecular alterations is essential for therapeutic decisions such as inclusion in clinical trials, early access to therapies, or compassionate treatment. The objective of this study was to determine the re...
Autores principales: | Pinet, Sandra, Durand, Stéphanie, Perani, Alexandre, Darnaud, Léa, Amadjikpe, Fifame, Yon, Mathieu, Darbas, Tiffany, Vergnenegre, Alain, Egenod, Thomas, Simonneau, Yannick, Le Brun-Ly, Valérie, Pestre, Julia, Venat, Laurence, Thuillier, Frédéric, Chaunavel, Alain, Duchesne, Mathilde, Fermeaux, Véronique, Guyot, Anne, Lacorre, Sylvain, Bessette, Barbara, Lalloué, Fabrice, Durand, Karine, Deluche, Elise |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10009270/ https://www.ncbi.nlm.nih.gov/pubmed/36923436 http://dx.doi.org/10.3389/fonc.2023.1104659 |
Ejemplares similares
-
CHI3L1, NTRK2, 1p/19q and IDH Status Predicts Prognosis in Glioma
por: Deluche, Elise, et al.
Publicado: (2019) -
Neutrophil-to-lymphocyte ratio evolution is an independent predictor of early progression of second-line nivolumab-treated patients with advanced non-small-cell lung cancers
por: Dusselier, Matthieu, et al.
Publicado: (2019) -
Prospective evaluation of an anti-cancer drugs management programme in a dedicated oral therapy center (DICTO programme)
por: Deluche, Elise, et al.
Publicado: (2020) -
Impact de la Covid-19 dans la prise en charge des cancers broncho-pulmonaires au CHU de Limoges
por: Atlagh, L., et al.
Publicado: (2022) -
KLRC3, a Natural Killer receptor gene, is a key factor involved in glioblastoma tumourigenesis and aggressiveness
por: Cheray, Mathilde, et al.
Publicado: (2016)